Plain-English translation of NCT05802836 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers want to understand how a patient's immune system responds to emicizumab, a medication used to treat severe hemophilia A. This is an observational study, which means researchers will simply monitor and analyze blood samples that are already being collected during your routine medical visits. The goal is to learn how antibodies in your blood change—or don't change—while you're receiving this treatment.
Some patients with hemophilia A develop inhibitors, which are antibodies that fight against the body's clotting factor and make treatment less effective. Doctors need to better understand how this medication affects these inhibitors and antibodies so they can improve care for all hemophilia patients.
You likely qualify if…
You likely don't qualify if…
You will continue to receive your regular hemophilia care and treatment with no extra visits or procedures needed. Researchers will use leftover blood samples from your routine clinic visits to study how your body's antibodies are responding to the medication. The study simply involves researchers analyzing these routine samples—nothing new or invasive is required from you.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
Germany
Collaborators
Roche Pharma AG, Chugai Pharma Germany GmbH
Enrollment target
~100 participants
Started
April 2023
Primary completion
December 2028
Last updated on clinicaltrials.gov in July 2023.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Stephan Schultze-Strasser, Dr.
Goethe University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.